

THE PATHWAY
TO PRESCRIPTION
IS COMPLICATED



**LET MICROSCAN
GRAM-NEGATIVE AND
GRAM-POSITIVE PANELS
BE YOUR LABORATORY'S GUIDE.**

Powered by the DxM MicroScan WalkAway systems
and LabPro software



MULTI-DRUG RESISTANT ORGANISMS (MDROs) ARE THE CAUSE OF:




> **2.8 million
infections¹**
+
**35,000
deaths
annually¹**

MicroScan conventional panels are your trusted pathway to prescription—providing antimicrobial resistance detection to combat multi-drug resistant organisms (MDROs).

As the foundation of MicroScan ID/AST products, conventional panels deliver **gold-standard²** accuracy through real-time detection of growth and emerging resistance. This reduces the need for expensive repeat and ancillary testing, providing timely results your laboratory can trust. Our MIC and combo panels help your laboratory get in front of the most prevalent and dangerous MDROs.

DID YOU KNOW?

1 in 10



Urinary tract infections in the community are caused by ESBL *E. coli*³

1 in 3



Urinary tract infections in healthcare settings are caused by ESBL *E. coli*³

↑ 66% COMMUNITY-ONSET INFECTIONS

↑ 41% HEALTHCARE-ONSET INFECTIONS

ESBL-producing *E. coli* frequency has increased by 66% in community-onset and 41% in healthcare-onset urinary tract infections since 2014.³

Beckman Coulter's MicroScan panels feature drugs recommended by IDSA* to treat pyelonephritis and complicated urinary tract infections caused by ESBLs which include ertapenem, meropenem, imipenem-cilastatin, ciprofloxacin, levofloxacin and trimethoprim-sulfamethoxazole.⁵

1/3 BLOODSTREAM INFECTIONS GLOBALLY

MRSA is the pathogen responsible for 1/3 of bloodstream infections globally.⁵

>11,000 DEATHS ANNUALLY

Methicillin resistant *Staphylococcus aureus* (MRSA) causes >11,000 deaths annually.⁴

Beckman Coulter's MicroScan panels have important drugs like vancomycin and ceftaroline to combat MRSA infections.

BECKMAN COULTER'S MICROSCAN PANEL OPTIONS

MicroScan panel options for routine and critical isolate testing will enable your laboratory to solve the toughest emerging resistance challenges.

Experience the benefits of MicroScan with our state-of-the-art selection of panels that provide:



UPDATED BREAKPOINTS
for CAP checklist confidence



EXPANDED DILUTIONS
for future breakpoint changes



NEW DRUGS
For treating resistant Gram-negative infections such as ceftazidime-avibactam, meropenem-vaborbactam and ceftolozane-tazobactam



HEIGHTENED SECURITY
with new LabPro v5.0 software platform

MICROSCAN GRAM-NEGATIVE COMBO PANELS



		SELECT SERIES								
		Panel Name	Neg Urine Combo 84	Neg Urine Combo 85	Neg Urine Combo 86	Neg Urine Combo 89	Neg Urine Combo 90	Neg Urine Combo 101	Neg Urine Combo 102	Neg Urine Combo 103
		MicroScan Catalog Number	B1017-434	B1017-435	B1017-436	C48639	C48640	C89643	C89644	C89645
		Languages	EN,ES,FR,PT	EN,ES,FR,PT	EN,ES,FR,PT	EN	EN	EN	EN	EN
AGENT CLASS	Abbr.	Antimicrobial Agent	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL
Aminoglycosides	Ak	Amikacin	16-32	16-32	16-32	-	-	-	-	-
	Gm	Gentamicin	4-8	4-8	4-8	4-8	4-8	2-8	2-8	2-8
	To	Tobramycin	4-8	4-8	4-8	2-8	4-8	2-8	2-8	2-8
Carbapenems	Etp	Ertapenem	0.5-1	0.5-1	0.5-1	-	0.5-2	0.5-1	0.5-1	0.5-1
	Imp	Imipenem	-	-	1-4	1-8	1-8	-	1-8	-
	Mer	Meropenem	1-8	1-8	1-8	1-8	1-8	1-8	1-8	1-8
Cephems (1st)	Cfz	Cefazolin	2-16	2-16	2-16	2-16	2-16	2-16	2-16	2-16
Cephems (1st)	Cf	Cephalothin	-	-	-	-	-	-	-	-
Cephems (2nd)	Crm	Cefuroxime	4-16	-	-	4-16	-	-	-	4-16
Cephems (3rd)	Cft	Cefotaxime ¹	2, 8-32	2, 8-32	-	-	-	-	-	-
Cephems (3rd)	Caz	Ceftazidime ¹	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16
Cephems (3rd)	Cax	Ceftriaxone	1-2, 8, 32	1-2, 8, 32	1-2, 8, 32	1-2, 8, 32	1-2	1-2	1-2	1-2
Cephems (4th)	Cpe	Cefepime	2-16	2-16	2-16	-	2-16	2-16	2-16	2-16
Cephems (cephamycin)	Ctn	Cefotetan	-	16-32	-	-	-	-	-	-
	Cfx	Cefoxitin	8-16	-	8-16	-	-	-	8-16	-
ESβL		ESβL Confirmation Test ¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	CftE	ESβL Screen - Cefotaxime	1	1	-	-	-	-	-	-
Fluoroquinolones	Cp	Ciprofloxacin	1-2	1-2	1-2	0.25-2	0.25-2	0.25-2	0.25-2	0.25-2
	Cp-S	Ciprofloxacin-S	-	-	-	-	-	-	-	-
	Lvx	Levofloxacin	2-4	2-4	2-4	0.5-4	0.5-4	0.5-4	-	0.5-4
Folate pathway antagonist	T/S	Trimethoprim-sulfamethoxazole	2/38	2/38	2/38	2/38	2/38	2/38	2/38	2/38
Fosfomycins	Fos	Fosfomicin	-	-	-	-	-	-	-	-
Monobactam	Azt	Aztreonam	4-16	4-16	4-16	-	-	4-16	4-16	4-16
Nitrofurantoin	Fd	Nitrofurantoin	32-64	32-64	32-64	32-64	32-64	32-64	32-64	32-64
Penicillins	Am	Ampicillin	8-16	8-16	8-16	8-16	8-16	8-16	8-16	8-16
Tetracyclines	ERV	Eravacycline	-	-	-	-	0.5	-	-	-
	Min	Minocycline	-	4-8	-	4-8	-	4-8	-	-
	Te	Tetracycline	4-8	4-8	4-8	4-8	-	-	4-8	4-8
	Tgc	Tigecycline	-	-	2-4	-	-	-	-	-
β-lactam combinations	Aug	Amoxicillin-clavulanate	-	8/4-16/8	-	8/4-16/8	8/4-16/8	-	8/4-16/8	-
	A/S	Ampicillin-sulbactam	4/2-16/8	8/4-16/8	8/4-16/8	-	8/4-16/8	8/4-16/8	4/2-16/8	8/4-16/8
	CZA	Ceftazidime-avibactam	-	-	8/4-16/4	4/4-16/4	4/4-16/4	8/4-16/4	-	8/4-16/4
	C/T	Ceftolozane-tazobactam	-	-	-	-	-	-	-	-
	MEV	Meropenem-vaborbactam	-	-	-	4/8-8/8	2/8-8/8	2/8-8/8	-	-
	P/T	Piperacillin-tazobactam	16/4, 64/4	16/4, 64/4	16/4, 64/4	16/4-64/4	16/4, 64/4	8/4-64/4	8/4-64/4	8/4-64/4
Total antibiotic tests / panel			22	23	23	20	21	20	20	20

¹ ESβL confirmation test includes the following agents & dilutions: Cefotaxime 2, 16; Ceftazidime 1, 8; Cefotaxime-clavulanate 0.5/4, 4/4; Ceftazidime-clavulanate 0.25/4, 2/4

² A=*Acinetobacter baumannii*

³ P=*Enterobacteriaceae and Pseudomonas aeruginosa*

MICROSCAN GRAM-NEGATIVE MIC PANELS



		SELECT SERIES				SPECIALTY MIC		
		Panel Name	Neg MIC 45	Neg MIC 53	Neg MIC 54	Neg MIC 56	ESβL plus	Detect Neg MIC 2*
		MicroScan Catalog Number	B1017-424	B1017-432	B1017-433	C42464	B1027-101	B1020-102B
		Languages	EN,ES,FR,PT	EN,ES,FR,PT	EN,ES,FR,PT	EN	EN,ES,FR,PT	EN
AGENT CLASS	Abbr.	Antimicrobial Agent	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL
Aminoglycosides	Ak	Amikacin	16-32	16-32	16-32	16-32	–	2-32
	Gm	Gentamicin	1-8	2-8	1-8	2-8	–	0.5 (RUO) ⁴ 1-8 (IVD)
	To	Tobramycin	1-8	2-8	1-8	2-8	–	–
Carbapenems	Dor	Doripenem	–	0.5-2	–	–	–	–
	Etp	Ertapenem	0.5-1	0.5-1	0.5-1	0.5-1	–	–
	Imp	Imipenem	0.5-8	1-8	0.5-4	1-8	0.5-16	–
	Mer	Meropenem	1-8	1-8	1-8	1-8	0.5-16	0.5-32
Cephems (1st)	Cfz	Cefazolin	2-16	2-16	2-16	2-16	–	–
Cephems (2nd)	Crm	Cefuroxime	4-16	4-16	4-16	4-16	–	–
Cephems (3rd)	Cft	Cefotaxime ¹	2-32	2, 8-32	2-32	2, 8-32	0.5-128	0.5-1 (RUO) ⁴ 2-64 (IVD)
Cephems (3rd)	Caz	Ceftazidime ¹	1-16	1, 4-16	1, 4-16	1, 4-16	0.5-128	0.5-32
Cephems (3rd)	Cax	Ceftriaxone	1-32	1-32	1-32	1-2, 8, 32	1-64	1-64
Cephems (4th)	Cpe	Cefepime	2-16	2-16	2-16	2-16	1-32	1-32
Cephems (cephamycin)	Ctn	Cefotetan	–	–	16-32	–	1-32	–
	Cfx	Cefoxitin	8-16	8-16	–	8-16	2-32	–
Cephems (oral)	Cpd	Cefpodoxime	–	–	–	–	0.5-64	–
ESβL		ESβL Confirmation Test ¹	Yes	Yes	Yes	Yes	Yes	Yes
	CftE	ESβL Screen - Cefotaxime	1	1	1	1	–	–
Fluoroquinolones	Cp	Ciprofloxacin	1-2	1-2	1-2	0.25-2	–	–
	Cp-S	Ciprofloxacin-S	–	0.06-0.5	0.06-0.5	–	–	–
	Lvx	Levofloxacin	0.25-4	2-4	0.5-4	0.5-4	–	0.12-4
	Mxf	Moxifloxacin	–	2-4	–	2-4	–	–
Folate pathway antagonist	T/S	Trimethoprim-sulfamethoxazole	2/38	2/38	2/38	0.5/9.5-2/38	–	0.5/9.5-2/38, 8/152
Fosfomycins	Fos	Fosfomycin	–	–	–	–	–	32-64 (RUO) ⁴
Monobactam	Azt	Aztreonam	4-16	4-16	4-16	4-16	0.5-64	2-32
Nitrofurantoin	Fd	Nitrofurantoin	32-64	32-64	32-64	32-64	–	–
Penicillins	Am	Ampicillin	8-16	8-16	8-16	8-16	–	–
	Pi	Piperacillin	16, 64	–	–	–	16-64	–
Polymyxins	Cl-A	Colistin A ²	–	–	–	–	–	2-4 (RUO) ⁴
	Cl-E, P	Colistin E, P ³	–	–	–	–	–	2-4 (RUO) ⁴
Tetracyclines	Min	Minocycline	–	4-8	4-8	4-8	–	2-8
	Te	Tetracycline	4-8	4-8	4-8	4-8	–	–
	Tgc	Tigecycline	2-4	1-4	2-4	2-4	–	2-4
β-lactam combinations	Aug	Amoxicillin-clavulanate	4/2-16/8	8/4-16/8	4/2-16/8	8/4-16/8	–	–
	A/S	Ampicillin-sulbactam	1/0.5-16/8	4/2-16/8	1/0.5-16/8	4/2-16/8	–	1/0.5-32/16
	CZA	Ceftazidime-avibactam	–	4/4-16/4	4/4-16/4	4/4-16/4	–	2/4-16/4
	C/T	Ceftolozane-tazobactam	–	2/4-8/4	–	2/4-8/4	–	2/4-8/4
	MEV	Meropenem-vaborbactam	–	–	–	2/8-16/8	–	–
	P/T	Piperacillin-tazobactam	4/4-64/4	8/4-64/4	4/4-64/4	8/4-64/4	–	4/4-64/4
	Tim	Ticarcillin-clavulanate	8-64	–	–	–	–	–
Total antibiotic tests / panel			27	31	28	30	13	19

* Detect Neg MIC 2 panel requires special contract

¹ ESβL confirmation test includes the following agents & dilutions: Cefotaxime 2, 16; Ceftazidime 1, 8; Cefotaxime-clavulanate 0.5/4, 4/4; Ceftazidime-clavulanate 0.25/4, 2/4

² A=*Acinetobacter baumannii*

³ P=*Enterobacteriaceae and Pseudomonas aeruginosa*

⁴ For Research Use Only, not for diagnostic use.

MICROSCAN GRAM-POSITIVE COMBO/MIC PANELS




								SPECIALTY MIC		
		Panel Name	Pos Combo 43	Pos Combo 44	Pos Combo 45	Pos Combo 46	Pos MIC 34	Pos MIC 38	MICroSTREP plus 1	MICroSTREP plus 2
		MicroScan Catalog Number	B1017-217	B1017-218	B1017-219	B1017-220	B1017-216	B1017-222	B1027-201	B1027-202
		Languages	EN,ES,FR,PT	EN,ES,FR	EN,ES,FR,PT	EN,ES,FR,PT	EN,ES,FR,PT	EN,ES,FR,PT	EN,ES,FR,PT	EN,ES,FR,PT
AGENT CLASS	Abbr.	Antimicrobial Agent	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL
Aminoglycoside	Gm	Gentamicin	4-8	4-8	4-8	4-8	1-8	4-8	-	-
Anamycins	Rif	Rifampin	1-2	1-2	1-2	1-2	1-2	1-2	-	-
Carbapenems	Imp	Imipenem	-	-	-	-	-	4-8	-	-
	Mer	Meropenem	-	-	4-8	4-8	-	2-8	0.06-0.5	0.06-0.5
Cephems (1st)	Cfz	Cefazolin	-	8-16	8-16	8-16	4-16	8-16	-	-
Cephems (1st)	Cf	Cephalothin	-	-	-	-	-	8-16	-	-
Cephems (2nd)	Crm	Cefuroxime	-	-	-	8-16	-	-	0.25-2	0.25-2
Cephems (3rd)	Cft	Cefotaxime	-	-	-	8-32	-	8-32	0.25-2	0.25-2
Cephems (3rd)	Cax	Ceftriaxone	-	-	8-32	-	4-32	4-32	0.25-2	0.25-2
Cephems (4th)	Cpe	Cefepime	-	-	-	8-16	-	4-16	0.25-2	0.25-2
Cephems (anti-MRSA)	Cpt	Ceftaroline	0.5-4	0.5-2	0.5-2	1-2	0.5-4	0.5-4	-	-
Cephems (oral)	Cfr	Cefaclor	-	-	-	-	-	-	0.5-4	0.5-4
Fluoroquinolones	Cp	Ciprofloxacin	1-2	1-2	1-2	-	1-2	1-2	-	-
	Gat	Gatifloxacin	-	-	-	-	-	-	0.12-2	-
	Lvx	Levofloxacin	1-4	1-4	1-4	1-4	0.5-4	1-4	0.25-4	0.25-4
	Mxf	Moxifloxacin	0.5, 2-4	0.5-1, 4	-	-	0.25-4	-	-	0.25-4
Folate pathway antagonist	T/S	Trimethoprim-sulfamethoxazole	0.5/9.5-2/38	0.5/9.5-2/38	0.5/9.5-2/38	0.5/9.5-2/38	0.5/9.5-2/38	0.5/9.5-2/38	0.25/4.75-2/38	0.25/4.75-2/38
Glycopeptide	Va	Vancomycin	0.25-16	0.5-16	0.5-16	0.5-16	0.25-16	0.25-16	0.12-1	0.12-4
Lincosamides	Cd	Clindamycin	0.5-4	0.25-0.5, 2	0.5-4	0.5-2	0.25-4	0.25-4	0.06-0.5	0.06-0.5
Lipopeptides	Dap	Daptomycin	0.5-4	1, 4	1, 4	0.5-4	0.25-4	0.5-4	-	0.25-2
Macrolides	Azi	Azithromycin	-	2-4	2-4	-	-	2-4	0.25-2	0.5-2
	Cl	Clarithromycin	-	-	-	-	-	-	-	0.25-1
	E	Erythromycin	0.5-4	0.5-4	0.25-4	0.25-4	0.25-4	0.25-4	0.06-0.5	0.06-0.5
Nitrofurantoin	Fd	Nitrofurantoin	32-64	32-64	32-64	32-64	32-64	32-64	-	-
Oxazolidinones	Lzd	Linezolid	1-4	2-4	2-4	2-4	0.5-4	1-4	-	0.5-4
Penicillins	Am	Ampicillin	2-8	2-8	2, 8	2, 8	2-8	2, 8	0.06-4	0.06-4
	Ox	Oxacillin	0.25-2	0.25, 1-2	0.25-2	0.25, 1-2	0.25-2	0.25-2	-	-
	P	Penicillin	0.03, 0.12-0.25, 2, 8	0.03, 0.12-0.25, 2, 8	0.03, 0.12, 2, 8	0.03, 0.12-0.25, 2, 8	0.03-8	0.03-2	0.03-4	0.03-4
Phenicol	C	Chloramphenicol	-	8-16	-	-	8-16	-	1-16	1-16
Antimicrobial Resistance Screens	CfxS	Cefoxitin Screen	4	4	4	4	4	4	-	-
	ICd	Inducible Clindamycin Test	4/0.5	4/0.5	4/0.5	4/0.5	4/0.5	4/0.5	-	-
	GmS	Gentamicin Synergy Screen	500	500	500	500	500	500	-	-
	StS	Streptomycin Synergy Screen	1000	1000	1000	1000	1000	1000	-	-
Streptogramins	Syn	Synercid	1-2	0.5-2	-	1-2	0.25-2	0.5-2	-	-
Tetracyclines	Te	Tetracycline	4-8	4-8	4-8	4-8	2-8	4-8	0.5-4	0.5-4
	Tgc	Tigecycline	0.25-1	-	-	0.25-0.5	0.12-1	0.25-1	-	-
β-lactam combinations	Aug	Amoxicillin-clavulanate	-	4/2	4/2	4/2	-	4/2	0.5/0.25-4/2	0.5/0.25-4/2
	A/S	Ampicillin-sulbactam	-	8/4-16/8	8/4-16/8	-	-	8/4-16/8	-	-
	P/T	Piperacillin-tazobactam	-	-	4/4-8/4	-	-	8/4	-	-
Total antibiotic tests / panel			23	27	27	27	26	32	18	21



Powered by the DxM MicroScan WalkAway systems and LabPro software. Enable your laboratory to optimize and safe-guard patient care while reducing risks, costs and operational burden associated with detecting emerging antimicrobial resistance.

LEARN MORE ABOUT WHAT BECKMAN COULTER'S MICROSCAN PANELS CAN OFFER YOUR MICROBIOLOGY LABORATORY:

[Click Here](#)
or
SCAN THIS!



References

1. Antibiotic resistance threats in the US 2019- CDC
2. Kalorama United States Market for In Vitro Diagnostic Tests, 2017, pg. 878
3. Raphael, E., Glymour, M. M., & Chambers, H. F. (2021). Trends in prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. *Antimicrobial resistance and infection control*, 10(1), 118. <https://doi.org/10.1186/s13756-021-00983-y>
4. Nichols, H. (2020). All you need to know about MRSA. *MedicalNewsToday*. <https://www.medicalnewstoday.com/articles/10634>
5. World Health Statistics 2022, pg. 33

*IDSA- Infectious Disease Society of America

© 2023 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact 2023-11789

